---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-003166"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:57:28.695726+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# NeuroOne issues shareholder letter; no specific financial or operational metrics disclosed

## Summary
- CEO Dave Rosa discusses company achievements, progress, and strategy in letter dated Jan 14, 2025.
- Letter does not contain specific revenue, earnings, or guidance figures.
- Letter posted to company website and furnished under Regulation FD.
- No material new information beyond general business update.

## SEC filing metadata
- accession: 0001213900-25-003166
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025003166/0001213900-25-003166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025003166/ea0227550-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-003166
- JSON: https://secwatch.observer/filing/0001213900-25-003166.json
- Plain text: https://secwatch.observer/filing/0001213900-25-003166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.